Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.64 |
| ▸ | BRAF | P15056 | 9/20 | 0.64 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.51 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | FLT1 | P17948 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 3/20 | 0.44 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2191884 | 0.90 | LCK (0.53) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2855529 | 0.90 | KDR (0.51) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2851666 | 0.89 | KDR (0.52) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2859583 | 0.88 | KDR (0.61) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2851199 | 0.88 | KDR (0.52) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2853938 | 0.87 | KDR (0.47) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2851235 | 0.86 | KDR (0.62) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2858591 | 0.86 | KDR (0.49) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2858582 | 0.85 | KDR (0.49) | KDRBRAFPDGFRBKITFLT1 | |
| SCHEMBL2851596 | 0.84 | KDR (0.56) | KDRBRAFPDGFRBKITFLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2184285-B1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
| EP-2184285-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | KDR 983/4885BRAF 1/4885PDGFRB 1509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.